Latest Health News

EMVision Medical Devices has hit key enrolment milestones in its pivotal brain scanner trial, expanded clinical endpoints, and maintained a strong cash position with $17.1 million on hand.

Starpharma launches a fully underwritten $32 million entitlement offer to fund the Phase 1 trial of its DEP® HER2-Lutetium radiopharmaceutical and accelerate its targeted oncology asset development.

Cyclopharm has landed a major US expansion deal with University Hospitals Cleveland, deploying Technegas® across 11 sites simultaneously and boosting its recurring revenue base in the Midwest.

Recce Pharmaceuticals has expanded its intellectual property footprint with a key patent granted in Vietnam for its RECCE® anti-infective drugs, reinforcing its presence in a critical Southeast Asian market grappling with high antibiotic resistance.

HeraMED's Phase 1 pilot with Lee Health confirms strong patient adoption and operational efficiency for its digital maternity care platform, setting the stage for broader US rollout.

H2G Limited has received a $774,632.77 R&D tax incentive refund, reinforcing its cash reserves and supporting its renewable energy strategy through 2027. The company plans to update shareholders on progress in its upcoming quarterly report.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Visionflex Group turned the corner with positive operating cash flow in Q4 FY26 and the launch of its unattended access capability, while securing new contracts to expand its virtual healthcare footprint.

CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).

Future Generation Global (ASX: FGG) posted a robust 22.7% total shareholder return for the year to June 2026, driven by share price gains and fully franked dividends, while increasing its interim dividend by 5%.

Mayfield Childcare has pulled its FY26 earnings guidance amid rising costs and regulatory shifts, while cautiously advancing its Mayfield 360 allied health initiative.

Renascor Resources' cost study estimates its hydrofluoric acid-free purification method can produce battery-grade graphite at about US$459 per tonne, positioning it as a competitive ex-China alternative to conventional HF-based processes.